ORPHA Stock Overview
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||kr.1.29|
|52 Week High||kr.109.10|
|52 Week Low||kr.1.10|
|1 Month Change||-53.93%|
|3 Month Change||-84.61%|
|1 Year Change||-96.17%|
|3 Year Change||-97.44%|
|5 Year Change||n/a|
|Change since IPO||-98.39%|
Recent News & Updates
|ORPHA||DK Biotechs||DK Market|
Return vs Industry: ORPHA underperformed the Danish Biotechs industry which returned -17% over the past year.
Return vs Market: ORPHA underperformed the Danish Market which returned 1% over the past year.
|ORPHA Average Weekly Movement||21.4%|
|Biotechs Industry Average Movement||8.1%|
|Market Average Movement||6.3%|
|10% most volatile stocks in DK Market||10.7%|
|10% least volatile stocks in DK Market||3.8%|
Stable Share Price: ORPHA is more volatile than 90% of Danish stocks over the past 3 months, typically moving +/- 21% a week.
Volatility Over Time: ORPHA's weekly volatility has decreased from 27% to 21% over the past year, but is still higher than 75% of Danish stocks.
About the Company
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease.
Orphazyme Fundamentals Summary
|ORPHA fundamental statistics|
Is ORPHA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ORPHA income statement (TTM)|
|Cost of Revenue||kr.0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Jun 07, 2022
|Earnings per share (EPS)||-23.95|
|Net Profit Margin||-6,429.52%|
How did ORPHA perform over the long term?See historical performance and comparison
Is Orphazyme undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ORPHA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ORPHA's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: ORPHA is unprofitable, so we can't compare its Price-To-Earnings Ratio to the European Biotechs industry average.
PE vs Market: ORPHA is unprofitable, so we can't compare its Price-To-Earnings Ratio to the Danish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ORPHA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ORPHA is good value based on its Price-To-Book Ratio (0.3x) compared to the DK Biotechs industry average (5.6x).
How is Orphazyme forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orphazyme has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Orphazyme performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ORPHA is currently unprofitable.
Growing Profit Margin: ORPHA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ORPHA is unprofitable, and losses have increased over the past 5 years at a rate of 49.2% per year.
Accelerating Growth: Unable to compare ORPHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ORPHA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: ORPHA has a negative Return on Equity (-507.08%), as it is currently unprofitable.
How is Orphazyme's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ORPHA's short term assets (DKK403.7M) exceed its short term liabilities (DKK223.7M).
Long Term Liabilities: ORPHA's short term assets (DKK403.7M) exceed its long term liabilities (DKK37.6M).
Debt to Equity History and Analysis
Debt Level: ORPHA has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ORPHA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if ORPHA has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ORPHA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Orphazyme current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ORPHA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ORPHA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ORPHA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ORPHA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ORPHA has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Anders Vadsholt (52 yo)
Mr. Anders Fink Vadsholt, M.Sc., M.B.A., serves Chief Executive Officer since 2022 & Chief Financial Officer since May 2016 of Orphazyme A/S (formerly known as Orphazyme ApS) and served as its Interim Chie...
CEO Compensation Analysis
Compensation vs Market: Anders's total compensation ($USD1.24M) is above average for companies of similar size in the Danish market ($USD410.50K).
Compensation vs Earnings: Anders's compensation has increased whilst the company is unprofitable.
Experienced Board: ORPHA's board of directors are considered experienced (5.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Orphazyme A/S's employee growth, exchange listings and data sources
- Name: Orphazyme A/S
- Ticker: ORPHA
- Exchange: CPSE
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr.45.553m
- Shares outstanding: 35.31m
- Website: https://www.orphazyme.com
Number of Employees
- Orphazyme A/S
- Ole Maaløes Vej 3
- Capital Region of Denmark
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/26 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.